Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791.
MAbs. 2021.
PMID: 33974508
Free PMC article.